Ahmad Kabbani, MD
Nephrology · Macon, GANPI 1528328796
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $12,116 of the $16,496 with a category attached, or 73.4%. 35 manufacturers reported payments, led by Amgen at 40.6% of the total. Reporting peaked in 2023 at $6,942 and has fallen 83.1% since, to $1,172 in 2025. Among nephrology clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 523 payments — averaging $31.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$7K
- AstraZeneca$2K
- Daiichi Sankyo Inc.$934
- Aurinia Pharma U.S., Inc.$901
- Otsuka America Pharmaceutical, Inc.$866
- Bayer$665
- plus $4K from 29 others
What the payments were for
- Speaking & faculty fees$2,72717%
- Travel & lodging$1,2828%
- Food & beverage$12,11673%
- Education$3722%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 90 | $6,697 |
| AstraZeneca(2 entities) | 92 | $2,124 |
| Daiichi Sankyo Inc. | 46 | $934 |
| Aurinia Pharma U.S., Inc. | 39 | $901 |
| Otsuka America Pharmaceutical, Inc. | 31 | $866 |
| Bayer | 41 | $665 |
| Vifor Pharma, Inc. | 32 | $642 |
| Travere Therapeutics, Inc. | 33 | $578 |
| Akebia Therapeutics Inc | 23 | $526 |
| Mallinckrodt Hospital Products Inc. | 9 | $343 |
| Ardelyx, Inc. | 7 | $264 |
| Fresenius USA Marketing, Inc. | 14 | $233 |
| Novartis | 10 | $222 |
| Baxter Healthcare | 2 | $205 |
| Xeris Pharmaceuticals, Inc. | 8 | $160 |
| Boston Scientific | 3 | $151 |
| Scpharmaceuticals Inc. | 2 | $135 |
| GSK | 8 | $127 |
| Mallinckrodt Enterprises LLC | 2 | $104 |
| Calliditas Therapeutics US Inc. | 5 | $97 |
| OPKO Pharmaceuticals, LLC | 4 | $84 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $66 |
| Alnylam Pharmaceuticals Inc. | 3 | $57 |
| Novo Nordisk | 2 | $40 |
| Medtronic | 1 | $34 |
| Apellis Pharmaceuticals, Inc. | 2 | $32 |
| Liberty Surgical Inc. | 1 | $32 |
| Shire North American Group Inc | 2 | $32 |
| Ultragenyx Pharmaceutical Inc. | 2 | $28 |
| EMD Serono, Inc. | 1 | $28 |
| Lilly USA, LLC | 1 | $22 |
| Boehringer Ingelheim | 1 | $21 |
| Fresenius USA Manufacturing, Inc. | 1 | $18 |
| Seqirus USA Inc | 1 | $16 |
| Johnson & Johnson | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KRYSTEXXA$4,734
- LUPKYNIS$350
- XPHOZAH 30 MG$148
- Vafseo$125
- LOKELMA$125
- JYNARQUE$119
- Renal - PD$113
- FARXIGA$111
- ACTHAR$111
- FUROSCIX$110
How this compares
$16,496 in reported general payments places this provider in the 90th percentile of 388 nephrology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KrystexxaPegloticase | 24 | $680,671 |
| AuryxiaFerric Citrate | 15 | $51,072 |
| Sevelamer Carbonate | 46 | $9,992 |
| Clonidine | 43 | $6,416 |
| Potassium Citrate ErPotassium Citrate | 28 | $4,442 |
| Midodrine Hcl | 41 | $3,123 |
| Nifedipine ErNifedipine | 138 | $3,083 |
| Calcium Acetate | 54 | $3,052 |
| Losartan Potassium | 347 | $2,343 |
| Allopurinol | 207 | $2,216 |
| Amlodipine Besylate | 411 | $2,064 |
| Bumetanide | 44 | $1,982 |
| Potassium Chloride | 99 | $1,652 |
| Doxazosin Mesylate | 112 | $1,621 |
| Hydralazine Hcl | 127 | $1,525 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenKrystexxa | $6,697 | $680,67124 claims |
| Akebia Therapeutics IncAuryxia | $526 | $51,07215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 388 nephrology providers in Georgia.
Other nephrology in Macon
- Sagar PanseMacon$542K
- Kimathi BlackwoodMacon$64K
- Reuben EllisMacon$27K
- Sheldon ShoreAtlanta$474K
- James TumlinLawrenceville$434K
- Salvatore ChillemiMarietta$287K
- Christina KleinAtlanta$137K
- Mary MuonekeAtlanta$119K
- Don WilliamsonAugusta$104K
- Frederic Rahbari OskouiAtlanta$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.